Cost-effectiveness analysis on elderly pneumococcal vaccination in the Netherlands: Challenging the Dutch Health Council's adviceZeevat, F., van der Schans, J., Boersma, W. G., Boersma, C. & Postma, M. J., Oct-2019, In : Vaccine. 37, 43, p. 6282-6284 3 p.
Research output: Contribution to journal › Article › Academic › peer-review
- PharmacoTherapy, Epidemiology and Economics
- Pharmacoepidemiology and Pharmacoeconomics
- Value, Affordability and Sustainability (VALUE)
- Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET)
- Microbes in Health and Disease (MHD)
- Methods in Medicines evaluation & Outcomes research (M2O)
Recently, the Dutch Health Council advised on elderly pneumococcal vaccination favouring the conventional polysaccharide vaccine over the novel conjugated vaccine. This advice was strongly inspired by a cost-effectiveness analysis considered to show favourable outcomes for the polysaccharide but not for the conjugated vaccine. We argue that using the same data and methods as presented by the Health Council, a different perspective on the results leads to a conclusion that not only the polysaccharide but also the conjugated pneumococcal vaccine is cost-effective. Our alternative perspective concerns the use of realistic vaccine prices, and applying an adequate time horizon for cost-effectiveness modelling. Notably, for one-off vaccination of 65-years old elderly, in all investigated analyses, also the conjugated vaccine seems cost-effective; i.e. well below the threshold of €20,000 per quality-adjusted life year, reflecting the most stringent threshold used for vaccines in the Netherlands.
|Number of pages||3|
|Early online date||9-Sep-2019|
|Publication status||Published - Oct-2019|
- Elderly pneumococcal vaccination, Polysaccharide vaccine, Conjugated vaccine, Cost-effectiveness, The Netherlands, Dutch Health Council advice, CONJUGATE VACCINE